Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition that may result from sarcomeric mutations or infiltrative disorders such as transthyretin amyloid cardiomyopathy (ATTR-CM) [1]. 99mTechnetium bone scintigraphy (99mTBS) has emerged as a key non-invasive tool for diagnosing ATTR-CM [2,3]. This imaging modality has demonstrated high sensitivity and specificity in differentiating ATTR-CM from other causes of left ventricular hypertrophy (LVH) [1,4]. Prior studies have primarily focused on the diagnostic yield and prevalence of ATTR-CM in patients with unexplained LVH and ATTR-CM is increasingly recognized as an underdiagnosed contributor to heart failure [5], but data regarding the impact of scintigraphy on clinical outcomes are scarce [1,6].
